Drug Combo Proves Powerful Against Lung Cancer Buffalo NY

A two-drug combination treatment in Buffalo proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

MICHAEL KRABAK, MD
(716) 565-0355
45 Spindrift Drive
Buffalo, NY
DONALD TRUMP, MD
(716) 845-2300
Elm And Carlton Street
Buffalo, NY
BRIAN MCGRATH, MD
(716) 859-1531
100 High Street
Buffalo, NY
Ellis Glenn Levine, MD
716-845-8547
Elm and Carlton St
Buffalo, NY
Brian Edward McGrath, MD
716-859-5600
100 High St Rm B-280
Buffalo, NY
Eunice Wang
(716) 689-1901
Elm And Carlton St
Buffalo, NY
MOHAMED AHMED, MD
(716) 298-4869
6934 Williams Road
Niagara Falls, NY
FOONG MING LAM, MD
(716) 626-3033
300 International Drive
Buffalo, NY
Eunice Sue Wang, MD
716-845-3544
Elm and Carlton St
Buffalo, NY
William Gress Kraybill, MD
716-845-3284
Elm and Carlton St
Buffalo, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Prostate Cancer Buffalo NY
Regular exercise may help protect men from prostate cancer, says a new study. U.S. researchers looked at 190 men who had a prostate biopsy and found that those who were moderately active -- anything equivalent to walking at a moderate pace for several hours a week -- were significantly less likely to be diagnosed with prostate cancer.
- Exercise for Breast Cancer Survival Buffalo NY
- Fungal Infection Treatments Buffalo NY
- Hormone Therapy for Lung Cancer Buffalo NY
- Side Effect Of Chemotherapy Drugs Buffalo NY
- Genetic Clues for Skin Cancer Therapies Buffalo NY
- Risks for Childhood Cancer Survivors Buffalo NY
- Delayed Prostate Cancer Therapy Buffalo NY
- Hormone Therapy for Breast Cancer Buffalo NY